Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 6Neoplasm Metastasis 2Colorectal Neoplasms 2Solid Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Osteosarcoma 1Neuroblastoma 1Gastrointestinal Neoplasms 1Borderline Resectable Pancreatic Cancer 1Biliary Tract Neoplasms 1Advanced Esophageal Squamous Cell Cancer 1

Interventions

Injections 4apatinib 3Cisplatin 3Capecitabine 3toripalimab 2alpha-Synuclein 2Oxaliplatin 2Gemcitabine 2Drug Therapy 2Docetaxel 2trametinib 1tislelizumab 1tesetaxel 1surufatinib 1spartalizumab 1pyrotinib 1pemigatinib 1pembrolizumab 1nimotuzumab 1mogamulizumab 1irinotecan sucrosofate 1fludarabine 1famitinib 1dalpiciclib 1camrelizumab 1YM753 compound 1Vemurafenib 1Taxes 1SHR-1701 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Solid Tumor × irinotecan sucrosofate × Clear all
NCT04569916 2020-09-30

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
30 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡